Intervertebral disc degeneration stands as a predominant contributor to chronic back and neck pain globally, presenting an immense clinical challenge due to its progressive nature and limited treatment options. Traditional therapies predominantly address symptom management rather than halting or reversing the degenerate cascade. A critical, yet underexplored, facet of this pathological process is cellular senescence—whereby disc cells enter a state of permanent growth arrest and acquire a senescence-associated secretory phenotype (SASP). This phenotype propagates local inflammation and extracellular matrix degradation, accelerating tissue breakdown and functional decline.
Emerging research spearheaded by Professor Makarand V. Risbud at Thomas Jefferson University targets this pathological senescence using senolytic agents—compounds that selectively eliminate senescent cells. His team’s investigation centers on the SM/J mouse model, which demonstrates spontaneous early-onset intervertebral disc degeneration influenced by genetic predisposition. This model provides an invaluable system to probe early molecular drivers of disease and test novel interventions prior to irreversible structural damage.
In their comparative study, two pharmacological senolytic strategies were evaluated: navitoclax, an inhibitor of BCL-2 family anti-apoptotic proteins, and a dasatinib–quercetin (DQ) cocktail with a broader senescence-targeting spectrum. The comprehensive approach integrated histological, molecular, advanced imaging, and high-throughput transcriptomic analyses to delineate how these treatments modulate disc pathology over time. This multifaceted methodology enabled the elucidation of cellular and genomic dynamics underpinning therapeutic responses.
Investigations revealed that SM/J mice harbor elevated markers of cellular senescence as early as four weeks of age, a temporal window preceding overt structural abnormalities. This finding fundamentally challenges the traditional view that senescence arises solely as a consequence of mechanical or age-related degeneration. Instead, it positions senescence as an early, causal driver of disc deterioration, particularly in genetically susceptible individuals. Senescent cells trigger inflammatory cascades and extracellular matrix remodeling, thereby undermining disc integrity and biomechanics.
Crucially, dasatinib–quercetin treatment conferred remarkable attenuation of degeneration severity compared to untreated controls. Disc specimens from DQ-treated mice exhibited better preservation of the nucleus pulposus architecture, reduced fibrotic remodeling, and notably diminished expression of canonical senescence markers including p19^ARF and p21. Concurrently, inflammatory signaling pathways were significantly dampened, highlighting the dual anti-senescent and anti-inflammatory effects of DQ. In contrast, navitoclax failed to elicit comparable molecular or histopathological improvements, underscoring the importance of drug-specific mechanisms.
Delving deeper, transcriptomic profiling unraveled that DQ remodels broad gene expression networks tied to inflammation, cellular stress responses, and tightly controlled regulation of the cell cycle. Among the pivotal insights was the identification of JNK (c-Jun N-terminal kinase) signaling as a nodal hub in disease progression and therapeutic modulation. JNK orchestrates stress-activated pathways that intersect senescence induction, inflammatory cytokine production, and matrix catabolism, making its regulation critical to maintaining disc homeostasis.
Functional validation came from experiments using human degenerative disc cells, where pharmacological inhibition of JUN signaling mimicked key beneficial effects of dasatinib–quercetin therapy. Reduced senescence-associated β-galactosidase activity and lowered pro-inflammatory gene expression reinforced JUN’s role as a central regulatory axis. These findings suggest that JUN signaling integrates and propagates degenerative cues, representing an attractive pharmacologic target for intervention.
Beyond advancing mechanistic understanding, these results have profound translational implications. They demonstrate that senotherapy—especially with pathway-selective agents like dasatinib and quercetin—can potentially delay early disc degeneration by mitigating cellular senescence and interrupting inflammatory feedback loops. This might pave the way for novel clinical strategies focused on early-stage intervention, thereby preserving disc structure and function before irreversible damage ensues.
Moreover, the study accentuates that the efficacy of senolytics is highly context-dependent, influenced by tissue-specific molecular landscapes and underlying genetic vulnerabilities. This highlights the necessity for precision medicine frameworks tailored to individual molecular phenotypes. Broad-spectrum senescent cell clearance is unlikely to be universally effective, advocating instead for targeted modulation of key signaling pathways such as JNK for maximum therapeutic benefit.
This research also opens avenues to explore senescence-associated pathologies beyond spinal degeneration, including other musculoskeletal disorders marked by chronic inflammation and matrix degradation. The intersection of cellular senescence, inflammation, and extracellular matrix remodeling appears to constitute a common pathological axis in aging tissues. Understanding and manipulating this nexus might revolutionize regenerative medicine approaches and therapies aimed at mitigating age-related functional decline.
Professor Risbud’s work exemplifies the power of integrative experimental techniques combining animal models and human cell biology to yield insights with direct clinical relevance. His team’s identification of JUN signaling as a critical convergence point underscores the potential for repurposing existing kinase inhibitors or designing novel modulators within senotherapeutic regimens.
In summary, the study delivers compelling preclinical evidence that dasatinib-quercetin senolytic treatment significantly delays the onset and progression of intervertebral disc degeneration in genetically predisposed SM/J mice. By attenuating senescence-associated molecular pathways and curbing inflammation, this therapeutic strategy preserves disc tissue architecture and functionality. These findings illuminate new mechanistic paradigms and therapeutic targets, offering hope for innovative interventions in degenerative spine diseases and broader musculoskeletal aging.
Subject of Research: Animals
Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice
News Publication Date: April 14, 2026
References: 10.1038/s41413-026-00526-4
Image Credits: Professor Makarand V. Risbud, Thomas Jefferson University, USA
Keywords: Intervertebral disc degeneration, cellular senescence, senolytics, dasatinib-quercetin, navitoclax, JNK signaling, inflammation, extracellular matrix remodeling, musculoskeletal aging, regenerative medicine, SM/J mouse model, gene expression
Tags: cellular senescence in spinal discsdasatinib–quercetin cocktail for senolysisearly intervertebral disc degeneration treatmentextracellular matrix degradation in spineinflammation in intervertebral disc diseasemolecular mechanisms of disc agingnavitoclax effects on disc cellspharmacological interventions targeting senescent cellssenescence-associated secretory phenotype in discssenolytic drug combination for disc degenerationSM/J mouse model for disc degenerationtranscriptomic analysis of disc degeneration
